Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Reduced fecal short-chain fatty acids levels and the relationship with gut microbiota in IgA nephropathy.

Tytuł:
Reduced fecal short-chain fatty acids levels and the relationship with gut microbiota in IgA nephropathy.
Autorzy:
Chai L; Deparment of Nephrology, Ningbo Hwamei Hospital, University of Chinese Academy of Sciences, No.41, Xibei street, Zhejiang Province, 315010, Ningbo, China.; Life and Health Industry Research Institute, 315010, Ningbo, Zhejiang Province, China.
Luo Q; Deparment of Nephrology, Ningbo Hwamei Hospital, University of Chinese Academy of Sciences, No.41, Xibei street, Zhejiang Province, 315010, Ningbo, China.; Life and Health Industry Research Institute, 315010, Ningbo, Zhejiang Province, China.
Cai K; Deparment of Nephrology, Ningbo Hwamei Hospital, University of Chinese Academy of Sciences, No.41, Xibei street, Zhejiang Province, 315010, Ningbo, China.; Life and Health Industry Research Institute, 315010, Ningbo, Zhejiang Province, China.
Wang K; Deparment of Nephrology, Ningbo Hwamei Hospital, University of Chinese Academy of Sciences, No.41, Xibei street, Zhejiang Province, 315010, Ningbo, China.; Life and Health Industry Research Institute, 315010, Ningbo, Zhejiang Province, China.
Xu B; Deparment of Nephrology, Ningbo Hwamei Hospital, University of Chinese Academy of Sciences, No.41, Xibei street, Zhejiang Province, 315010, Ningbo, China. .; Life and Health Industry Research Institute, 315010, Ningbo, Zhejiang Province, China. .
Źródło:
BMC nephrology [BMC Nephrol] 2021 Jun 03; Vol. 22 (1), pp. 209. Date of Electronic Publication: 2021 Jun 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: London : BioMed Central, [2000-
MeSH Terms:
Gastrointestinal Microbiome*
Dysbiosis/*etiology
Fatty Acids, Volatile/*analysis
Feces/*chemistry
Glomerulonephritis, IGA/*complications
Adult ; Biomarkers/analysis ; Blood Chemical Analysis ; Case-Control Studies ; Feces/microbiology ; Female ; Glomerulonephritis, IGA/microbiology ; Humans ; Male
References:
Nephrol Dial Transplant. 2011 Aug;26(8):2544-9. (PMID: 21245129)
PLoS One. 2014 Jun 12;9(6):e99006. (PMID: 24922509)
Clin Sci (Lond). 2019 Sep 10;133(17):1857-1870. (PMID: 31467135)
Nutr Clin Pract. 2006 Dec;21(6):639-40; author reply 640. (PMID: 17119172)
Pharmacol Res. 2019 Mar;141:366-377. (PMID: 30639376)
Future Microbiol. 2015;10(9):1485-504. (PMID: 26347019)
Acta Pharmacol Sin. 2016 Feb;37(2):228-34. (PMID: 26775659)
Genome Biol. 2011 Jun 24;12(6):R60. (PMID: 21702898)
Ecotoxicology. 2020 Nov;29(9):1347-1357. (PMID: 32772242)
Mol Nutr Food Res. 2005 Jun;49(6):601-8. (PMID: 15841496)
Pediatr Nephrol. 2018 Jan;33(1):53-61. (PMID: 28389744)
Theranostics. 2020 Apr 6;10(12):5398-5411. (PMID: 32373220)
Clin Nutr. 2019 Apr;38(2):615-630. (PMID: 29496274)
BMC Nephrol. 2020 Mar 13;21(1):97. (PMID: 32169051)
Clin J Am Soc Nephrol. 2020 Jul 1;15(7):973-982. (PMID: 32354727)
Lipids. 2018 Jan;53(1):77-84. (PMID: 29488641)
Lett Appl Microbiol. 2003;37(4):304-8. (PMID: 12969493)
Poult Sci. 2009 May;88(5):943-8. (PMID: 19359681)
Vet Microbiol. 2012 Mar 23;155(2-4):324-31. (PMID: 21930351)
PLoS One. 2014 Mar 21;9(3):e91756. (PMID: 24658533)
Sci Rep. 2019 Mar 20;9(1):4736. (PMID: 30894560)
Nephrol Dial Transplant. 2011 Feb;26(2):414-30. (PMID: 21068142)
Biochim Biophys Acta Mol Basis Dis. 2020 Jun 1;1866(6):165764. (PMID: 32169506)
Nat Med. 2014 Feb;20(2):159-66. (PMID: 24390308)
Front Immunol. 2015 Nov 03;6:554. (PMID: 26579129)
Ren Fail. 2020 Nov;42(1):629-637. (PMID: 32660366)
Metabolism. 2017 Mar;68:20-30. (PMID: 28183450)
Am J Physiol Gastrointest Liver Physiol. 2013 Dec;305(12):G900-10. (PMID: 24136789)
Int Immunopharmacol. 2019 Oct;75:105832. (PMID: 31473434)
Adv Nutr. 2016 Nov 15;7(6):1080-1089. (PMID: 28140325)
Exp Clin Endocrinol Diabetes. 2017 Feb;125(2):98-105. (PMID: 28049222)
mBio. 2019 Jan 29;10(1):. (PMID: 30696735)
Adipocyte. 2014 Nov 14;4(2):81-8. (PMID: 26167409)
Nat Rev Nephrol. 2018 Jul;14(7):442-456. (PMID: 29760448)
Ann Intern Med. 2009 May 5;150(9):604-12. (PMID: 19414839)
Semin Nephrol. 2018 Sep;38(5):504-512. (PMID: 30177022)
Clin J Am Soc Nephrol. 2014 Feb;9(2):265-70. (PMID: 24262508)
Hypertens Res. 2019 Feb;42(2):123-140. (PMID: 30504819)
J Clin Med. 2018 Sep 30;7(10):. (PMID: 30274359)
J Clin Gastroenterol. 2013 Sep;47(8):678-83. (PMID: 23442839)
Sci Rep. 2016 May 27;6:26752. (PMID: 27229737)
Cell. 2016 Jun 2;165(6):1332-1345. (PMID: 27259147)
Nutrients. 2019 Aug 18;11(8):. (PMID: 31426593)
FEMS Microbiol Lett. 2009 May;294(1):1-8. (PMID: 19222573)
Contributed Indexing:
Keywords: Gut microbiota; IgA nephropathy; Short-chain fatty acids
Substance Nomenclature:
0 (Biomarkers)
0 (Fatty Acids, Volatile)
Entry Date(s):
Date Created: 20210604 Date Completed: 20220304 Latest Revision: 20231111
Update Code:
20240104
PubMed Central ID:
PMC8173972
DOI:
10.1186/s12882-021-02414-x
PMID:
34082732
Czasopismo naukowe
Background: IgA nephropathy(IgAN)) is the common pathological type of glomerular diseases. The role of gut microbiota in mediating "gut-IgA nephropathy" has not received sufficient attention in the previous studies. The purpose of this study was to investigate the changes of fecal short-chain fatty acids(SCFAs), a metabolite of the intestinal microbiota, in patients with IgAN and its correlation with intestinal flora and clinical indicators, and to further investigate the role of the gut-renal axis in IgAN.
Methods: There were 29 patients with IgAN and 29 normal control subjects recruited from January 2018 to May 2018. The fresh feces were collected. The fecal SCFAs were measured by gas chromatography/mass spectrometry and gut microbiota was analysed by16S rDNA sequences, followed by estimation of α- and β-diversity. Correlation analysis was performed using the spearman's correlation test between SCFAs and gut microbiota.
Results: The levels of acetic acid, propionic acid, butyric acid, isobutyric acid and caproic acid in the IgAN patients were significantly reduced compared with control group(P < 0.05). Butyric acid(r=-0.336, P = 0.010) and isobutyric acid(r=-0.298, P = 0.022) were negatively correlated with urea acid; butyric acid(r=-0.316, P = 0.016) was negatively correlated with urea nitrogen; caproic acid(r=-0.415,P = 0.025) showed negative correlation with 24-h urine protein level.Exemplified by the results of α-diversity and β-diversity, the intestinal flora of IgAN patients was significantly different from that of the control group. Acetic acid was positively associated with c_Clostridia(r = 0.357, P = 0.008), o_Clostridiales(r = 0.357, P = 0.008) and g_Eubacterium_coprostanoligenes_group(r = 0.283, P = 0.036). Butyric acid was positively associated with g_Alistipes (r = 0.278, P = 0.040). The relative abundance of those were significantly decreased in IgAN group compared to control group.
Conclusions: The levels of fecal SCFAs in the IgAN patients were reduced, and correlated with clinical parameters and gut microbiota, which may be involved in the pathogenesis of IgAN, and this finding may provide a new therapeutic approach.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies